BACKGROUND Advanced pancreatic cancer is resistant to chemotherapeutic drugs,
resulting in limited treatment efficacy and poor prognosis. Combined administration of the …

Background This study aims to comprehensively summarize the currently available
evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced …

Background Pancreatic cancer is considered as a chemoresistant neoplasm with extremely
dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced …

PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed
dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer. METHODS: We …

Context The combination of gemcitabine and erlotinib is a standard first-line treatment for
unresectable, locally advanced or metastatic pancreatic cancer. We reviewed our single …

Pancreatic adenocarcinoma is one of the leading causes of cancer deaths in Japan.
Erlotinib plus gemcitabine (GEM) combination therapy provided significant improvements in …

Background Gemcitabine has been recognized as a standard chemotherapy in advanced
pancreas cancer (APC). We conducted a phase II study of a triple combination regimen …

Objective Erlotinib plus gemcitabine is approved in Japan for the treatment of metastatic
pancreatic cancer. The POLARIS surveillance study investigated safety (focusing on …

Background Advanced pancreatic cancer (APC) has a very poor prognosis. Despite 8 phase
III trials over 10 years testing the addition of cytotoxic or biologic agents to gemcitabine …